Hot Investor Mandate 4: Hong Kong PE Firm Invests in Clinical Stage Biopharmaceuticals, Devices and Diagnostics for China Market

5 Jan

A private equity firm headquartered in Hong Kong currently manages over US$4 billion in assets and invests across several industry sectors including healthcare. The firm is interested in pre-growth and growth stage companies. Typical investment size ranges from US$5-10 million in Series A rounds. The firm seeks to lead but is open to syndicating with co-investors. The firm is now looking for opportunities in China, the US, and Canada.

Within healthcare, the firm focuses on medical devices and diagnostic technologies that have a China angle. The firm prefers products that have achieved clinical validation with proven advantages. The firm is also interested in clinical-stage biopharmaceutical opportunities as well as health information technology. The firm is opportunistic in terms of indication areas but is less interested in orphan diseases.

The firm is looking for experienced management teams with track record of success. The firm typically requests board representation in its portfolio companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: